Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Gilead and Global Fund to supply new HIV drug, lenacapavir, to low-income countries at cost.
Gilead Sciences and the Global Fund have agreed to supply the new HIV prevention drug, lenacapavir, to low-income countries.
Approved in the U.S., this twice-yearly injection can reduce HIV transmission risk by over 99.9%.
Gilead will provide the drug at cost to reach up to 2 million people over three years.
The World Health Organization is reviewing it, and the first shipments are expected to reach Africa by the end of the year.
44 Articles
Gilead y el Fondo Global para suministrar un nuevo medicamento contra el VIH, lenacapavir, a los países de bajos ingresos a un costo.